

INGRID GLIMELIUS *Curriculum Vitae*

MD, PhD, Associate Professor, Senior consultant Oncology, Uppsala University and Akademiska Hospital and
Division of Clinical Epidemiology, Department of Medicine, Karolinska Institutet Stockholm, Sweden.

Ingrid.Glimelius@igp.uu.se

Professional preparation

Senior consultant Oncology	Akademiska Uppsala	2019
Assistant Professor (<i>Docent</i>) Oncology	Uppsala University	2016
Consultant Oncology	Akademiska Uppsala	2013
Consultant Internal Medicine	Hudiksvall and Uppsala	2011
PhD thesis, Oncology	Uppsala University	2009
Medical Doctor Degree, MD	Uppsala University	2001

Current position

Senior consultant Oncology (MD), 40%	Akademiska Uppsala	May 19 -
Senior Clinical Investigator Award, 60%	Swedish Cancer Society	Jan 2020-

Previous Position

Internship	Hudiksvall	2001-2002
Resident Internal Medicine	Hudiksvall	2002-2007
Resident Oncology	Uppsala	2007-2013
Consultant Oncology	Uppsala	2013-2019
Post-Doc	Karolinska, Clinical Epidemiology 50%	2011-2016
Post-Doc Scholarship	Swedish Medical Society	Jan-May 14
Post-Doc Scholarship	Swedish Society of Medical Research	May14-May16
Research position (30% 3 years)	Akademiska Hospital Uppsala	Jan 17-Dec 19
Research position (25% 3 years)	Swedish Cancer Society	Jan 17-Dec 19

PhD-student's main supervisor

P Hollander (graduated)	Uppsala University	2014-2018
C Sköld	Uppsala University	Apr 2016-
A Nikkarinen	Uppsala University	May 2019-

Co-supervisor

L Chen (graduated)	Karolinska Institutet	2013-2017
C Weibull (graduated)	Karolinska Institutet	2014-2018
N Øvergaard	Uppsala University	May14-
I Lagerlöf	Linköping University	Nov14-

Graduate students

Supervisor of nine students (20 weeks/person)	Uppsala University	2007-2021
---	--------------------	-----------

Teaching

Medical school, oncology	Uppsala University, 190 hours	2010-
Research school in epidemiology	Karolinska Institutet, 20 hours	2013-
Specialist training malignant hematology	Akademiska Uppsala, 12 hours	2015-
Examiner for master thesis medical school	Uppsala University	2017-

Expert groups

Mantle Cell Lymphoma Swedish representative	Nordic Lymphoma Group	2015-
National Research School Oncology (NATION)	Uppsala University representative	2017-
Research representative	Swedish Chronic Lymphocytic Leukemia group	2015-
Research representative	Swedish Hodgkin lymphoma group	2009-
Author Swedish treatment guidelines	Mantle Cell Lymphoma	2015
Author Swedish treatment guidelines	Hodgkin lymphoma	2016
Secretary	Sweden-Norway Testicular Cancer group	2016-
Author Swenoteca treatment guidelines	Testicular cancer	2019

Reviewer/editor

Halftime seminar board, PHD review board several times. Reviewer: Blood, Lancet Oncology, Acta Oncol, Leuk & Lymph, Exp Hematol/Oncol, Int J Cancer, Oncotarget **Guest editor** Journal of Internal Medicine 2017

Courses

Good Clinical Practice

Investigator Site Personnel ICH-GCP

2015-2020

Ongoing clinical TrialsSwedish PI **ENRICH**, a British Nordic phase III study for elderly mantle cell lymphoma patientsPI Uppsala **VALERIA**, a phase I/II study of relapsed mantle cell lymphoma patientsSwedish PI **ALTAMIRA**, a phase II study for elderly MCL patients testing Acalabrutinib + Rituximab using a MRD-driven designPrincipal Investigator Uppsala **Testis ABC**, phase III study for seminoma patientsSub investigator in several lymphoma clinical trials at Uppsala University Hospital during several years, including the **TRIANGLE** trial

INGRID GLIMELIUS *Publication list*

62 published Original peer-reviewed articles
 4 published Review articles
h-index: 14 (web of science)

Nine selected publications

1. **Glimelius I**, E Smedby K, Albertsson-Lindbladh A, Eloranta S, Jerkeman M, Weibull E C. Mantle cell lymphoma patients unmarried or with low education are less often transplanted leading to lower survival.
Accepted blood advances, January 2021
2. Joana de Matos Rodrigues*, Anna Nikkarinen*, Peter Hollander, Caroline Weibull, Riita Rääty, Arne Kolstad, Rose-Marie Amini, Anna Porwit, Mats Jerkeman, Sara Ek* and **Glimelius I*** *These authors contributed equally. Infiltration of CD163, PD-L1 and FOXP3 positive cells adversely affects outcome in mantle cell lymphoma (MCL) patients independent of established risk factors
Accepted British Journal of Haematology, January 2021
3. Rodrigues J, May Hassan, Catja Freiburghaus, Christian W. Eskelund, Anna Kwiecinska, Christian Geisler, Riikka Rääty, Arne Kolstad, Christer Sundström, **I Glimelius**, Kirsten Grønbaek, Anna Porwit, Mats Jerkeman and Sara Ek. Immunohistochemical p53 assessment as a screening tool for TP53 missense mutations in mantle cell lymphoma
British Journal of Haematology, Aug 4 2020 (E-pub ahead of print)
4. **Glimelius I**, Eloranta S, Ekström K, Jerkeman M, Weibull C.
 Comorbidities and sex differences in causes of death among mantle cell lymphoma patients – A nationwide population-based cohort study
Br J Haematology, Br J Haematol, 2020 Apr;189(1):106-116
5. Biccler J*, **Glimelius I***, Eloranta S, Smeland BK, de Nully Brown P, Hjort Jakobsen L, Frederiksen H, Jerkeman M, Fosså A, Andersson ML T, Holte H, Bøgsted M, Christoffer El-Galaly T*, Smedby KE*. Relative mortality, relapse risk, and loss of lifetime in young Hodgkin lymphoma patients: A Nordic Lymphoma Group study. ***Both first and last authors contributed equally**
Journal of Clinical Oncology, March 20, 2019
6. Weibull C, Johansson A, Eloranta S, Smedby KE, Björkholm M, Lambert P, Dickman P, **Glimelius I**
 Contemporarily treated Hodgkin lymphoma patients have childbearing potential in line with matched comparators
Journal of Clinical Oncology, 2018 Sep 10;36 (26)
7. **Glimelius I***, Eloranta S*, Ekberg S, Chang T E, Neovius M, Ekström Smedby K. Increased healthcare use up to 10 years among relapse-free Hodgkin lymphoma survivors in the era of intensified chemotherapy and limited radiotherapy * Contributed equally
American Journal of Haematology, 2017 Mar;92(3):251-258
8. Weibull CE, Eloranta S, Ekström Smedby K, Kristinson SY, Björkholm M, Lambert P, Dickman PW*, **Glimelius I***. Pregnancy and the risk of relapse in patients diagnosed with Hodgkin lymphoma?
 *Contributed equally to last authorship
Journal of Clinical Oncology, 2016 Feb 1;34(4):337-44 (Selected as News Digest November 2015)
9. Travis LB, Hill DA, Dores GM, Gospodarowicz M, van Leeuwen FE, Holowaty E, Glimelius B, Andersson M, Wiklund T, Lynch CF, Van't Veer MB, **Glimelius I**, Storm H, Pukkala E, Stovall M, Curtis R, Boice JD, Gilbert E. Breast Cancer Following Radiotherapy and Chemotherapy Among Young Women With Hodgkin Disease.
Jama, 2003; 290(4): 465-475.

Complete Publication list, Original articles, newest first

1. Joana de Matos Rodrigues*, Anna Nikkarinen*, Peter Hollander, Caroline Weibull, Riita Rääty, Arne Kolstad, Rose-Marie Amini, Anna Porwit, Mats Jerkeman, Sara Ek* and **Glimelius I*** *These authors contributed equally. Infiltration of CD163, PD-L1 and FOXP3 positive cells adversely affects outcome in mantle cell lymphoma (MCL) patients independent of established risk factors
Accepted British Journal of Haematology, January 2021
2. **Glimelius I**, E Smedby K, Albertsson-Lindbladh A, Eloranta S, Jerkeman M, Weibull E C. Mantle cell lymphoma patients unmarried or with low education are less often transplanted leading to lower survival.
Accepted blood advances, January 2021
3. Wåsterlid, T, Gradel Oren K, Eloranta, S, **Glimelius I**, Jerkeman M, El-Galaly TC, Fredriksen H, Smedby KE. Clinical characteristics and outcomes among patients 2347 patients aged ≥ 85 years with major lymphoma subtypes: A Nordic Lymphoma Group Study,
Accepted British Journal of Haematology, November 2020
4. C M. Kitahara, D Slettebø Daltveit, A Ekbom, A Engeland, M Gissler, MsocSci, **I Glimelius**, T Grotmol, Y Trolle Lagerros, L Madanat-Harjuoja, T Männistö, H Toft Sørensen, S Tretli, R Troisi, T Bjørge Risk of thyroid cancer in offspring in relation to maternal health and *in utero* perinatal exposures
Accepted The Lancet Diabetes and Endocrinology, October 2020
5. Eskelund, CW, Dimopoulos K, Kolstad A, **Glimelius I** Gjerdrum LR, Sonnevi K, Josefsson P, Nilsson-Ehle H, Bentzen H, Fagerli U, Kuittinen O, Haaber J, Niemann C, Pedersen LB, Larsen MT, Geisler CH, Hutchings M, Jerkeman M, Grønbaek K A descriptive study of patients who relapsed after the Nordic mantle cell lymphoma trials: MCL2 and MCL3
Accepted HemaSphere, October 2020
6. A Sabba, C Mörth, S Hasselblom, G Hedstrom, M Flogegård, M Stern, PO Andersson, **I Glimelius**, G Enblad. Age is the most important predictor of survival in diffuse large B-cell lymphoma patients achieving EFS24 – a Swedish population-based study
Accepted British Journal of Haematology, September 2020
7. Daltveit DS, Leionen M, Ekbom A, Engeland A, Gissler M, **Glimelius I** Grotmol T, Ording A, Tretli S, Troisi R, Toft Sørensen H, Bjørge T. Cancer risk in individuals with major birth defects: A Nordic population-based case-control study among children, adolescents and young adults
Accepted British Medical Journal, October 2020
8. Persson Skare T, Sjöberg E, Roche FP, Berglund M, Lindskog CL, **Glimelius I**, Gholia A, Enblad G, Amini R*, Claesson-Welsh L* Marginal zone lymphoma survival increased by expression of histidine-rich glycoprotein in tumor cells and lack of stanniocalcin-2. *Contributed equally
Accepted E J Hematology, July 2020 (E-pub ahead of print)
9. Rodrigues J, May Hassan, Catja Freiburghaus, Christian W. Eskelund, Anna Kwiecinska, Christian Geisler, Riikka Rääty, Arne Kolstad, Christer Sundström, **I Glimelius**, Kirsten Grønbaek, Anna Porwit, Mats Jerkeman and Sara Ek Immunohistochemical p53 assessment as a screening tool for TP53 missense mutations in mantle cell lymphoma
British Journal of Haematology, Aug 4 2020 (E-pub ahead of print)
10. K Larsson, M Mattsson, F Ebrahim, **I Glimelius**, M Höglund. Prevalence and Incidence of cardiovascular disease in Chronic Lymphocytic Leukaemia – a nationwide population-based study
British Journal of Haematology, 2020 June 9, (online ahead of print)
11. Ording A, Christensen BL, Bjørge T, Doody RD, Ekbom A, **Glimelius I**, Grotmol T, Larfors G, Mueller AB, Smedby EK, Tretli S, Troisi R, Toft Sørensen H. Birthweight and all-cause mortality after childhood and adolescent leukemia – a cohort study from Denmark, Norway, Sweden and Washington State (U.S.)
Acta Oncologica, 2020, July 29, vol 59 (issue 8)

12. Sköld C, Bjørge T, Leionen M, Ekblom A, Engeland A, Gissler M, Grotmol T, Ording A, Tretli S, Troisi R, Toft Sørensen H, **Glimelius I**. Pregnancy-related risk factors for non-epithelial ovarian cancer in parous women: A registry-based study
Br J Cancer 2020, Jul;(123) (1):161-166
13. Ekberg S, Smedby KE, **Glimelius I**, Nilsson-Ehle H, Goldkuhl C, Lewerin C, Jerkeman M, Eloranta S, Trends in the prevalence of Non-Hodgkin lymphoma overall and subtypes during the 21st century – A Swedish lymphoma register study
14. **Glimelius I**, Eloranta S, Ekström K, Jerkeman M, Weibull C. Prognostic Implications of Specific Comorbidities in Mantle Cell Lymphoma, a Swedish lymphoma registry study
Accepted Br J Haematol, August 2019
15. Lagerlöf I, Holte H, **Glimelius I**, Björkholm M, Enblad G, Erlanson M, Flug Ø, Fohlin H Fosså A, Goldkuhl C, Gustavsson A, Johansson A-S, Linderöth J, Nome O, Palma M, Åkesson L, Östenstad B, Raud C, Glimelius B and Molin D. Long-term outcome in patient with limited stage Hodgkin lymphoma treated with ABVD and limited field radiotherapy in Sweden and Norway
Accepted Br J Haematol, August 2019
16. Gerdtsson A, Håkansson U, Törnblom M, Jancke G, Negaard H, **Glimelius I**, Halvorsen D, Karlsdottir Å, Haugnes H, Andreassen K, Melsen Larsen S, Holmberg G, Wahlqvist R, Tandstad T, Cohn-Cedermark G, Ståhl O, Kjellman A. Surgical complications in post-chemotherapy retroperitoneal lymph node dissection for non-seminoma germ cell tumour, a population-based study from the Swedish Norwegian Testicular Cancer group
Accepted European Urology Oncology 7 Sep 2019 (E-pub ahead of print)
17. **Glimelius I***, Englund A*, Rostgaard K, Smedby E. K, Eloranta S, de Nully Brown P, Kamper P, Ljungman G, Hjalgrim LL, Hjalgrim H. *Contributed equally. Distribution of hospital care among paediatric and young adult Hodgkin lymphoma survivors – a population based cohort study from Sweden and Denmark
Cancer Medicine, July 2, 2019 (E-pub ahead of print)
18. Trabert, B, Troisi, R, Grotmol T, Ekblom A, Engeland A, Gissler M, **Glimelius I**, Madanat-Harjuoja L, Toft Sørensen H, Tretli, S, Ording Gulbech A, Bjørge T. Pregnancy-related factors and birth characteristics and risk of maternal endometrial cancer
Int J Cancer, June 7, 2019 (E-pub ahead of print)
19. Al-Jebari Y, **Glimelius I**, Berglund Nord C, Cohn-Cedermark G, Ståhl O, Rylander L, Giwercman A Impact of cancer therapy on risk of congenital malformations in children fathered by men treated for germ cell testicular cancer.
PLOS Medicine, 16(6): e1002816, June 4 2019
20. Biccler J*, **Glimelius I***, Eloranta S, Smeland BK, de Nully Brown P, Hjort Jakobsen L, Frederiksen H, Jerkeman M, Fosså A, Andersson ML T, Holte H, Bøgsted M, Christoffer El-Galaly T*, Smedby KE*. Relative mortality, relapse risk, and loss of lifetime in young Hodgkin lymphoma patients: A Nordic Lymphoma Group study. ***Both first and last authors contributed equally**
Journal of Clinical Oncology, March 20, 2019
21. Weibull C, Björkholm M, **Glimelius I**, Lambert P, Andersson T, Dickman P, Eloranta S. Temporal trends in treatment-related excess incidence of diseases of the circulatory system among Hodgkin lymphoma patients
Int J Cancer, Sep 1, 2019
22. Wästerlid T*, Mohammadi M*, Ekström-Smedby K, **Glimelius I**, Jerkeman M, Bottai M, Eloranta S The impact of comorbid disease history on all-cause and lymphoma-specific mortality in diffuse large B-cell lymphoma – a Swedish lymphoma register study
Journal of Internal Medicine, Apr 285(4) 2019
23. Gholiha, A, Hollander P, Hedström G, Sundström C, Smedby E K, Hjalgrim H, **Glimelius I**, Amini R-M, Enblad G.

High tumour plasma cell infiltration reflects an important microenvironmental component in classic Hodgkin lymphoma linked to presence of B symptoms.

Br J Haematology, Jan;184(2): 192-201, 2019

24. Hollander P, Amini R-M, Ginman B, Enblad G, **Glimelius I**.
PD-1+ and PD-L1+ leukocytes are constantly expressed in consecutive biopsies in the microenvironment of classical Hodgkin lymphoma.
PLOS ONE, Sep 27;13(9) 2018
25. Weibull C, Johansson A, Eloranta S, Smedby KE, Björkholm M, Lambert P, Dickman P, **Glimelius I**
Contemporarily treated Hodgkin lymphoma patients have childbearing potential in line with matched comparators
J Clinical Oncology, Sep 10;36 (26) 2018
26. Rebecca Troisi, Henrik Toft Sørensen, Tom Grotmol, **Ingrid Glimelius**, Anders Engeland, Mika Gissler, Britton Trabert, Anders Ekbohm, Anne Gulbech Ording, Steinar Tretli, Tone Bjørge.
Pregnancy Complications and Subsequent Breast Cancer Risk in the Mother: A Nordic population-based case-control study
Int J Cancer, Oct 15;143(8) 2018
27. Björkholm M, Weibull C, Eloranta S, Ekström-Smedby K, **Glimelius I***, Dickman PW*
Greater attention should be paid to developing therapies for elderly patients with Hodgkin lymphoma – a population-based study from Sweden, *Contributed equally
Eur J Haematology, 2018 July 4, 106-114
28. Sköld C, Bjørge T, Leionen M, Ekbohm A, Stephansson O, Engeland A, Gissler M, Grotmol T, Ording A, Tretli S, Troisi R, Toft Sørensen H, **Glimelius I**.
Preterm delivery increases the risk of ovarian cancer in parous women
Int J Cancer, Oct 15;143(8) 2018
29. Chen L, Eloranta S, Martling A, **Glimelius I**, Neovius M, Glimelius B, Smedby E Karin
Short- and long term risk of cardiovascular disease and thromboembolism following radiotherapy in rectal cancer – assessment based on four randomized controlled trials and a population-based register
Radiotherapy and Oncology, 2018 Mar;126(3):424-430
30. Hollander P, Rostgaard K, Ekström-Smedby K, Molin D, Loskog A, de Nully Brown P, Enblad G Amini RM, Hjalgrim H, **Glimelius I**.
The classical Hodgkin lymphoma tumor microenvironment presents with either innate, activated or anergic immune phenotype in which the latter is associated with inferior outcome
European Journal of Hematology, 2018 Jan;100(1):88-97
31. Hollander P, Kamper P, Smedby E.K, Enblad G, Mortensen J, Amini RM, d'Amore F, Molin D*, **Glimelius I***
High proportion of PD-1+ leukocytes in classical Hodgkin lymphoma microenvironment is associated with inferior prognosis
Blood Advances, 2017 Aug 8;1(18):1427-1439
32. Larfors G, **Glimelius I**, Eloranta S, Ekström-Smedby K,
Parental age and risk of lymphatic malignancies.
Am J Epidemiology, 2017 Nov 15; 186(10):1159-1167
33. Englund A*, **Glimelius I***, Rostgaard K, Smedby KE, Eloranta S, Molin D, Kuusk T, Brown PN, Kamper P, Hjalgrim H Ljungman G*, Hjalgrim L*.
Hodgkin lymphoma in children, adolescents and young adults – a comparative study of clinical presentation and treatment outcome * **Contributed equally**
Acta Oncologica, 2017 Aug 1:1-7
34. Baecklund F, Foo JN, Padyukov L, Hjalgrim H, Eloranta S, **Glimelius I**, Rosenquist R, Askling J, Smedby KE

- Possible interaction between cigarette smoking and HLA-DRB1 variation in the risk of follicular lymphoma
Am J Epidemiology, 2017 Apr 15; 185(8):681-687
35. **Glimelius I***, Eloranta S*, Ekberg S, Chang T E, Neovius M, Ekström Smedby K.
Increased healthcare use up to 10 years among relapse-free Hodgkin lymphoma survivors in the era of intensified chemotherapy and limited radiotherapy * Contributed equally
Am J Haematology, 2017 Mar;92(3):251-258
 36. Bjorge T, Gissler M, Ording A, Engeland A, **Glimelius I**, Leinonen M, Toft Sorensen H, Tretli S, Ekbohm A, Troisi R* Grotmol T*
Reproductive history and risk of colorectal adenocarcinoma: A population-based case-control study,
Br J Cancer, 2016 Nov 22;115(11):1416-1420
 37. Chen L, **Glimelius I**, Neovius M, Ekberg S, Martling A, Eloranta S, Ekström Smedby K.
Work loss duration and predictors following rectal cancer treatment among patients with and without pre-diagnostic work loss
Cancer Epidemiology Biomarkers and Prevention, 2016 Jun;25(6):987-94
 38. Kinch A, Sundström C, Tufveson G, **Glimelius I**.
Association between HLA-A1 and A2 types and Epstein - Barr virus status of post-transplant lymphoproliferative disorders
Leukemia and Lymphoma, 2016 Oct;57(10):2351-8
 39. Englund, A, Molin D, Enblad G, Roos G, **Glimelius I**, Ljungman G*, Amini R-M*.
The role of tumour-infiltrating eosinophils, mast cells and macrophages in classical and nodular lymphocyte predominant Hodgkin lymphoma in children
European J Hematology, 2016 Nov;97(5):430-438
 40. Mohammad, M, Hong S, Cao Y, **Glimelius I**, Ekbohm A, Weimin Y, Smedby E K.
The risk of lymphoid neoplasms in a Swedish population-based cohort of 337 437 patients undergoing appendectomy.
Scandinavian Journal of Gastroenterology, 2016;51(5):583-9
 41. Hallquist Everhov Å, Ekberg S, Linden Hirschberg A, Bergmark K, Flöter Rådestad A, **Glimelius I**, Ekström-Smedby K.
Lost work days in uterine cervical cancer survivors: impact of treatment and relapse
J Cancer Survivorship, 2016 Jun;10:514-23
 42. Weibull CE, Eloranta S, Ekström Smedby K, Kristinson SY, Björkholm M, Lambert P, Dickman PW*, **Glimelius I***.
Pregnancy and the risk of relapse in patients diagnosed with Hodgkin lymphoma? *Contributed equally to last authorship
Journal of Clinical Oncology, 2016 Feb 1;34(4):337-44 (**Selected as News Digest November 2015**)
 43. Mohammadi M, Cao Y, **Glimelius I**, Bottai M, Eloranta S, Ekström-Smedby K.
The impact of comorbid disease history on all-cause and cancer-specific mortality in myeloid leukemia and myeloma – a Swedish population-based study
BMC Cancer, 2015 Nov 5;15:850
 44. **Glimelius I**, Ekberg S, Jerkeman M, Chang ET, Björkholm M, Ekström-Smedby K*, Eloranta S*.
Long-term survival in young and middle-aged Hodgkin lymphoma patients in Sweden 1992-2009 – trends in cure proportions by clinical characteristics. *Contributed equally to last authorship.
American Journal of Hematology, 2015 Dec;90(12):1128-34
 45. Delahaye-Sourdeix M, Urayama KY, Gaborieau V, Johansson M, Chabrier A, Benavente Y, Nieters A, Becker N, Foretova L, Maynadié M, Staines A, Smedby KE, **Glimelius I**, Lightfoot T, Cocco P, Kiemeny L, Roman E, de Sanjosé S, Lathrop M, Melbye M, Brennan P, Diepstra A, van den Berg A, Hjalgrim H, Jarrett RF, McKay JD. A novel risk locus at 6p21.3 for Epstein-Barr virus positive Hodgkin lymphoma
Cancer Epidemiology Biomarkers and Prevention, 2015 Dec;24(12):1838-43
 46. Chen L, **Glimelius I**, Neovius M, Martling A, Eloranta S, Ekberg S, Martling A, Ekström-Smedby K.
Risk of disability pension in patients following rectal cancer treatment and surgery
British Journal of Surgery, 2015 Oct;102(11):1426-32

47. Hollander P, Petersen K, Chang E, Amini RM, Ekström-Smedby K, Glimelius B, Adami H-O, Melbye M, **Glimelius I**, Hjalgrim H. Autoimmune and atopic disorders and risk of Hodgkin lymphoma.
Am J Epidemiology, 2015 182 (7):624-632. **(Regarded as editor's choice October 2015)**
48. Nord C*, Olofsson SE*, **Glimelius I**, Ekberg S, Cohn Cedermark G, Cavallin-Ståhl E, Neovius M, Jerkeman M, Ekström-Smedby K. Sick leave and disability pensions among Swedish testicular cancer survivors – up to 10 years follow-up according to treatment modality. *contributed equally
Acta Oncologica 2015 Nov;54(10):1770-80
49. **Glimelius I**, Ekberg S, Linderöth J, Jerkeman M, Chang E.T., Neovius M and Ekström-Smedby K. Sick leave and disability pension in Hodgkin lymphoma survivors by stage, treatment and follow-up time – a population-based comparative study
J Cancer Survivorship, 2015 Dec;9(4):599-609
50. Monnereau A, Glaser S. L., Schupp C W, Ekström Smedby K, de Sanjosé S, Kane E, Melbye M, Forétova L, Maynadié M, Staines A, Becker N, Nieters A, Brennan P, Boffetta P, Cocco P, **Glimelius I**, Clavel J, Hjalgrim H and Chang ET Exposure to ultraviolet radiation and risk of Hodgkin lymphoma: a pooled analysis
Blood, 2013 Nov14;122(20):3492-9
51. **Glimelius I***, Qvarnström F*, Simonsson M, Ekwall A, Smedby E. K., Molin D, Amini R-M. Tissue microarray and digital image analysis: a methodological study with special reference to the microenvironment in Hodgkin Lymphoma. *Contributed equally.
Histopathology 2012 Jul;61(1):26-32.
52. **Glimelius I***, Rubin J*, Fischer M, Molin D, Amini RM, Venge P and Enblad G, The effect of eosinophil cationic protein on Hodgkin lymphoma tumour cell lines, *Contributed equally.
Experimental Haematology 2011 Aug 39(8) 850-858
53. **Glimelius I**, Rubin J, Rostgaard K, Amini RM, Simonsson M, Sorensen KM, , Ekström-Smedby K, Venge P, Hjalgrim H, Molin D, Enblad G. Predictors for histology, tissue eosinophilia and mast cell infiltration in Hodgkin lymphoma – a population based study.
Eur J Haematology 2011 Sep 87(3) 208-216
54. Carvalho R, Mahshid Y, Claesson HE, **Glimelius I**, Fischer M, Nilsson G. Expression of mast cell tryptases in Hodgkin and Reed-Sternberg cells.
Scand J Immunol 2008 Jan; 67(1) 53-6
55. **Glimelius I**, Edström A, Amini RM, Fischer M, Nilsson G, Sundström C, Enblad G, Molin D. IL-9 expression contributes to the cellular composition in Hodgkin Lymphoma.
Eur J Haematol 2006; 76: 278-283.
56. **Glimelius I**, Edström A, Fischer M, Nilsson G, Sundström C, Molin D, Amini R-M, Enblad G. Angiogenesis and mast cells in Hodgkin lymphoma.
Leukemia 2005 Dec; 19(12): 2360-2362.
57. **Glimelius I**, Molin D, Amini R-M, Gustavsson A, Glimelius B, Enblad G. Bulky disease is the most important prognostic factor in Hodgkin lymphoma stage IIB.
Eur J Haematol, 2003; 71(5): 327-333.
58. Travis LB, Hill DA, Dores GM, Gospodarowicz M, van Leeuwen FE, Holowaty E, Glimelius B, Andersson M, Wiklund T, Lynch CF, Van 't Veer MB, **Glimelius I**, Storm H, Pukkala E, Stovall M, Curtis R, Boice JD, Gilbert E. Breast Cancer Following Radiotherapy and Chemotherapy Among Young Women With Hodgkin Disease.
Jama, 2003; 290(4): 465-475.
59. Travis LB, Gospodarowicz M, Curtis RE, Clarke A, Andersson M, Glimelius B, Joensuu T, Lynch CF, van Leeuwen FE, Holowaty E, Storm H, **Glimelius I**, Pukkala E, Stovall M, Fraumeni Jr JF, Boice Jr. JD, Gilbert E. Lung Cancer Following Chemotherapy and Radiotherapy for Hodgkin's Disease.

J Natl Cancer Inst 2002;94(3): 182-192.

60. Molin D, Edström A, **Glimelius I**, Glimelius B, Nilsson G, Sundström C and Enblad G. Mast cell infiltration correlates with poor prognosis in Hodgkin's lymphoma. *Br J Haematol*, 2002: 119(1); 122-124

Thesis

61. **Glimelius I**, Hodgkin Lymphoma – an Interplay Between Tumour Cell and Microenvironment, thesis *Acta Universitatis Upsaliensis*, May 2009.

Book chapter

62. Enblad G, Molin, D, **Glimelius I**, Fischer M, Nilsson G. The potential role of innate immunity in the pathogenesis of Hodgkin Lymphoma. Bokkapitel
Hematol Oncol Clin North Am. 2007 Oct;21 (5) 805-23

Reviews

63. Troisi R, Bjørge T, Gissler M, Grotmol T, Kitahara M C Solbjörg Makalani M, Ordning A Sköld C, Toft Sørensen H, Trabert B, **Glimelius I** The role of pregnancy, perinatal factors, and hormones in Maternal Cancer Risk: A review of the evidence
Journal of Internal Medicine (JIM), 2018 May;283 (5): 430-445
64. **Glimelius I**, Diepstra A. Novel treatment concepts in Hodgkin lymphoma.
Journal of Internal Medicine (JIM), 2017 Mar;28(3):247-26
65. Palmarsdottir R, Kiesbye Övliisen, Tang Sverinsen M, **Glimelius I**, Smedby KE, El-Galaly TC Socioeconomic impact of Hodgkin lymphoma in young adults – a review
Leukemia and Lymphoma, June 6 (E-pub ahead of print)

Abstracts as presenting or senior author

66. **Glimelius I**, Eloranta S, Ekström K, Jerkeman M, Weibull C, Prognostic Implications of Specific Comorbidities in Mantle Cell Lymphoma, **Poster**, American Society of Haematology, December 2018
67. **Glimelius I**, Johansson A, Eloranta S, Smedby K, Björkholm M, Lambert P, Dickman P, Weibull C; Contemporarily treated Hodgkin lymphoma patients have childbearing potential in line with matched comparators **Oral**, 11th International Symposium on Hodgkin Lymphoma, Germany October 2018
68. **Glimelius I**, Amini RM, Ginman B, Molin D, Enblad G, Hollander P Expression of PD-1 and PD-L1 increase in consecutive biopsies in patients with classical Hodgkin lymphoma
Oral, 11th International Symposium on Hodgkin Lymphoma, Germany October 2018
69. **Glimelius I**, Amini RM, Ginman B, Molin D, Enblad G, Hollander P Expression of PD-1 and PD-L1 increase in consecutive biopsies in patients with classical Hodgkin lymphoma,
Oral, 11th International Symposium on Hodgkin Lymphoma, Germany October 2018
70. **Glimelius I** Active, Innate and Anergic immune response in risk and prognosis of Hodgkin lymphoma,
Invited speaker 10th International Symposium on Hodgkin Lymphoma, Germany October 2016
71. **Glimelius I**. Healthcare use among young Hodgkin lymphoma survivors in the era of intensified chemotherapy and limited radiotherapy **Oral**, Interlymph symposium Minnesota, USA June 2016
72. **Glimelius I**, Ekberg S, Linderöth J, Jerkeman M, Chang ET, Björkholm M, Ekström Smedby K, Eloranta S. Statistical cure and survival in Hodgkin lymphoma patients by clinical characteristics and treatment – a Swedish population-based study, **Oral**, InterLymph symposium, Holland Jun 2015.
73. **Glimelius I***, Rubin J*, Fischer M, Molin D, Amini RM, Venge P and Enblad G. The effect of eosinophil cationic protein on Hodgkin lymphoma tumour cell lines, *Contributed equally,
Poster at the 7th international symposium on Hodgkin Lymphoma Cologne, Germany 2007,
Haematologica - The Hematology Journal Nov 2007 92(5) 37-37
74. **Glimelius I**, Edström A, Amini RM, Fischer M, Nilsson G, Sundström C, Enblad G, Molin D. IL-9 expression contributes to the cellular composition in Hodgkin Lymphoma.
Poster at the 6th international symposium on Hodgkins lymphoma, Cologne sept 2004